🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thanks to everyone who made our #ASCO25 great. More #pallonc webinars coming this fall. Thanks to Dr Mazie Tsang, MD, MAS, MS for her years of fearless leadership. Excited to see where our co-champions Cristiane D Bergerot and Dr Joseph McCollom DO will lead us this coming year.

Thanks to Binaytara for hosting the first annual North Carolina Hematologic Malignancies Symposium in Durham chaired by Debbie Stephens UNC Lineberger. It was an honor to speak with all star lineup of speakers. education.binaytara.org/content/north-…

🚨Deadline Alert TOMORROW‼️ 📅 Tuesday, June 10 #ASCOQLTY25 Abstract submissions are due this week! Share your solutions-driven research & help shape the future of quality cancer care. Don’t miss the premier forum for innovation in care delivery! 👉 asco.org/quality

Unraveling the mysteries of molecular testing in AML….. 🕵️🧬🩸 for those interest in #AMLsm #LeuSM and #Hemepath Hope you find this video/podcast informative. w/ Amer Zeidan MBBS,MHS ‏عامر زيدان

I'm delighted to partner with ACCC on the development of educational content about acute myeloid leukemia (#AML). Take a look at our recent on-demand webinar, where we dive deeply into the how, what and why of bone marrow aspiration and biopsy: accc-cancer.org/home/learn/can…

Announcing the first EVER Journal of Clinical Oncology Art of Oncology Narrative Medicine Contest! 🎉✍️🎗️🩺🎉 We're looking for essays that explore the human experience of cancer and reflect on the experience of trainees and early career hematologists/oncologists. Apply Now! ascopubs.org/jco/art-oncolo…

An investigator-initiated clinical trial evaluating #Ruxolitinib and #Fostamatinib for steroid-refractory chronic #GVHD is now accruing at Duke Cancer, one of few combinatorial regimens being tested, based on work from #SarantopoulosLab. PIs Chenyu Lin, MD Mitch Horwitz #BMTsm

This was an amazing effort and practice changing study for LGL leukemia - cyclophosphamide is superior to MTX with respect to ORR with comparable safety - took 10 years to accrue but shows can do RCT in rare hem diseases #EHA25 #EHA2025

Impressive results of 7+3 + Ziftomenib in newly diagnosed AML patients with NPM1m or KMT2Ar presented by Harry Erba. We are embarking on a new era of menin inhibitors in combination with frontline therapy in newly Dx AML w/ NPM1m or KMT2Ar. European Hematology Association #EHA25

#EHA2025 #youngEHA Bleximenib with AZA+VEN for R/R and ND AML 👇🏽 presented by Dr. Andrew Wei #leusm #menin_inhibitors

CONGRESS | #EHA2025 | PRESENTATION Gail Roboz Weill Cornell Medicine shares findings from phase IIb of the ASCERTAIN-V clinical trial (NCT04657081) of all-oral decitabine-cedazuridine (DEC-C) + venetoclax (VEN), in patients with newly diagnosed AML ineligible for intensive induction

CONGRESS | #EHA2025 | PRESENTATION Harry Erba Duke Cancer presents updated phase Ia/b results from the KOMET-007 trial, of ziftomenib RP2D (600 mg QD) combined with intensive induction chemotherapy (7+3), in newly diagnosed NPM1m or KMT2Ar AML. Ziftomenib was well tolerated, and

#EHA2025 #youngEHA Great presentation by Dr. DiNardo, how to improve on VEN+HMA for intensive ineligible AML pts.. 1. Ven resistance mechanisms. 2. Novel targets 3. Ven triplets under development #leusm #AML #venetoclax_4_AML

CONGRESS | #EHA2025 | PRESENTATION Musa Yilmaz, MD MD Anderson Cancer Center shares updated results from a phase I/II trial of decitabine (DAC), venetoclax (VEN), plus quizartinib in newly diagnosed (n = 30) and R/R (n = 46) FLT3-ITDm AML. DAC+VEN+quizartinib response rates were high in the

#EHA2025 #EHA25 #ALL s/c blinatumomab for RR ALL, P1/1b data presented by Dr. Jabbour. 1. Given at 2 dose level, 250ug/500ug was better tolerated and selected for RP2D. 2. Responses were better compared to IV Blina. 3. Responses were seen among pts with prior IV blina exposed.

Real-world outcomes of TP53-mut #MPN are heterogeneous, with worse prognosis in accelerated/blast-phase disease, complex karyotype, and multi-hit #TP53, a U.S. #COMMAND consortium study featuring Duke Cancer faculty Chenyu Lin, MD as a co-author. British Journal of Haematology onlinelibrary.wiley.com/doi/10.1111/bj…

Every machine in a Hospital that diagnoses your body without cutting you open is based on a principle of Physics, discovered by a Physicist who had no interest in Medicine. If you think the world doesn’t need Basic Science, or that somehow Science has failed you, think again.

Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL) | Leukemia nature.com/articles/s4137…

📢 Out in NEJM Evidence 👫N=1132 pts; age 18-60 🔹ND #AML 🔹Consolidation with IDAC vs HIDAC 🔹5-yr OS = 59% vs 58% 🔹Lower incidence of myelosuppressio & AEs with IDAC ➡️ IDAC non inferior to HIDAC #leusm OncoAlert evidence.nejm.org/doi/pdf/10.105…

My lab’s 5-year NIH R01 grant, awarded to study gene therapy for hearing loss, was abruptly terminated. I want to share how this action has been incredibly harmful and disruptive, not just to my lab, but to the scientific process itself. 1/15